Adjunctive Dulaglutide in Relapsing-Remitting Multiple Sclerosis: A Randomized Open-Label Proof-of-Concept Trial.

Neurol Ther · 2026 · PMC13396319 · PMID 42321509

Europe PMC DOI

hedged sentence

0.0770

closest p · 1.5× alpha

0.0770

boldest claim

The sentences

showed a trendp = 0.077so close (0.05 < p ≤ 0.1)

For the non-dominant hand, the active group showed a trend toward improvement p = 0.077), and repeated-measures analysis indicated a significant effect of group × time interaction ( F 1,26 = 4.7, p = 0.039).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.